Using NeuroFlow's technology, the Medical Center is more effectively identifying patients with behavioral health needs in its Ambulatory Care Center and proactively connecting them to essential behavioral health and substance use disorder services
PHILADELPHIA, Feb. 5, 2026 /PRNewswire-PRWeb/ -- Bergen New Bridge Medical Center shared results from its partnership with NeuroFlow, a leading behavioral health technology company, that show how integrated, digital screening has already improved patient outcomes and compliance with key quality measures. Using NeuroFlow's IntegrateBH solution, patients have been screened for behavioral health needs – depression, anxiety, alcohol, and substance use – at a rate 14x higher than pre-NeuroFlow screening rates in the Medical Center's Ambulatory Care Center.
NeuroFlow collects depression, anxiety, and substance use assessments digitally from patients prior to their appointments at the Medical Center. Providers can access this data via tablet to quickly identify mental health or addiction challenges and refer patients to the care they need, including an integrated psychiatric nurse practitioner that supports same-day interventions and referral support.
"Our care teams can now more quickly identify behavioral health needs and navigate patients to the right level of care, often during the same visit, which can save lives," said Deborah Visconi, President & CEO, Bergen New Bridge Medical Center. "By using NeuroFlow, we have been able to provide rapid, measurable improvement for some of our most vulnerable patients."
The Medical Center participates in the New Jersey Quality Improvement Program (QIP-NJ), which incentivizes expanding access to care and improving behavioral health and substance use disorder outcomes. The program's benchmark requires that 80% of eligible patients receive substance use disorder and depression screening with appropriate follow-up care.
Prior to partnering with NeuroFlow, the Medical Center's screening rate for required assessments among eligible patients was only 5.8%. By introducing NeuroFlow, which uses SMS texts and tablets to screen patients in its Ambulatory Care Center, the Medical Center was able to dramatically increase the number of patients screened for these life-threatening conditions. The screening rate for substance use disorders and behavioral health rose to 81.6%, surpassing the benchmark established by QIP-NJ.
As a result, patients received critical care for life threatening conditions, and Bergen New Bridge was able to receive significant funding from QIP-NJ for achieving the required benchmark. As a safety net provider, the additional funding allowed the hospital to continue its mission to provide high-quality care to vulnerable populations.
NeuroFlow's flexible, patient-centric approach to data collection is unique in the market and was critical to the program's success. NeuroFlow offers screening through multiple channels—including mobile app, SMS, email, or in-person tablet assessments — which lowers patient barriers to completion. Bergen New Bridge and NeuroFlow partnered closely so that the NeuroFlow team had a strong understanding of the Ambulatory Care Center's existing workflows before implementation. NeuroFlow also analyzed the patient population to ensure optimal outreach before the screening platform was implemented. This partnership led to significant program improvements, including the addition of a psychiatric nurse practitioner to provide same-day behavioral health support. This helped the Medical Center meet QIP-NJ follow up requirements after positive screens, maximizing performance in the program.
"The key to improving quality measure performance isn't forcing providers to change how they work, it's removing friction from existing workflows," said Dr. Tom Zaubler, Chief Medical Officer, NeuroFlow. "Bergen New Bridge achieved these results through a combination of technology and high-touch human support which made conducting screening easier. NeuroFlow integrated seamlessly into the daily routine in the Ambulatory Care Center, which made its success much more attainable."
Health systems interested in learning more about Bergen New Bridge Medical Center's results can download the full case study here.
About Bergen New Bridge Medical Center
Bergen New Bridge Medical Center (BNBMC), a clinical affiliate of Rutgers, is a 1,070-bed hospital located at 230 East Ridgewood Avenue in Paramus, NJ. The Medical Center is both the largest hospital and licensed nursing home in NJ and the fourth largest, publicly owned hospital in the nation.
Bergen New Bridge, a not-for-profit safety net facility, provides high-quality comprehensive services, including acute and ambulatory care, mental health and substance use disorder treatment, long-term care, 24/7 emergency department, surgical suites, physical rehabilitation, pharmacy, laboratory, radiologic services (including digital mammography). The Medical Center also has satellite offices in Bergenfield, Englewood, and Paterson. Primary care and other health and wellness services are available at the hospital's CareRite Now centers located in select Inserra Supermarkets in Bergen County.
Bergen New Bridge is in network with all major New Jersey commercial insurance plans covering 99.91% of NJ residents and is a Veterans Community Care Provider. It is also a Leader in LGBTQ Healthcare Equality in the Human Rights Campaign (HRC) Healthcare Equality Index (HEI). Learn more at www.newbridgehealth.org.
About NeuroFlow
NeuroFlow helps risk-bearing healthcare organizations improve outcomes and cost of care in medically complex populations by surfacing and supporting behavioral health needs that typically go undetected and under-addressed. Across payors, providers, and the federal government, NeuroFlow's scalable technology and analytics capabilities empower organizations with the behavioral health insights they're missing to manage these populations in a financially sustainable way. Powered by deep expertise in whole-person care, NeuroFlow offers a path to risk predictability and proactive care that helps overcome the systemic challenges in today's healthcare ecosystem.
Media Contact
Ellen Harvey, NeuroFlow, 1 610-420-1724, [email protected], neuroflow.com
SOURCE NeuroFlow
Share this article